P/E của cổ phiếu SUPN là bao nhiêu?

SUPERNUS PHARMACEUTICALS INC (SUPN) hiện giao dịch ở mức P/E 117.66 lần.

ROE của cổ phiếu SUPN là bao nhiêu?

SUPERNUS PHARMACEUTICALS INC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -2.69%.

Tỷ suất cổ tức của SUPN là bao nhiêu?

SUPERNUS PHARMACEUTICALS INC có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của SUPN là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của SUPN ở mức 38/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu SUPN không?

Điểm AI Timing của SUPN là 27/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu SUPN thuộc ngành nào?

SUPERNUS PHARMACEUTICALS INC được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu SUPN (NASDAQ) | SUPERNUS PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

SUPN AI Analysis Summary

Our AI summary for SUPN: SUPERNUS PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 117.66, ROE of -2.69%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SUPN

SUPERNUS PHARMACEUTICALS INC

USD 44.63

-0.98 (-2.15%) Day Change

Watchlist Portfolio Compare Chart

117.66

P/E

0.01

D/E

-2.7%

ROE

-1.9%

ROA

0.00%

Div Yield

0.07

PEG

SUPERNUS PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 44.63 Price -0.98 (-2.15%) Day Change	NEWS SCORE: 99

SUPN Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) và Thời điểm mua ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	44.63
PBV / Sector	2.46 / 3.22
Earning Per Share	-0.49

PE / Sector	117.66 / 29.79
PEG or PE/Growth / Sector	0.07 / 0.13 GREAT
Average 1M Daily Value	31.98 M GREAT
Average 1W Daily Value	23.21 M GREAT

Yếu tố Kỹ thuật

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-3.74 / 15.21
NPM Average (%) / Sector	2.28 / -10.83
NPM Change Average (%) / Sector	1,194.09 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-1.93 / 8.15
ROA Average (%) / Sector	0.90 / 2.87
ROA Change Average (%) / Sector	1,217.14 / 112.70
ROE (%) / Sector	-2.69 / -1.02
ROE Average (%) / Sector	1.56 / 8.35
ROE Change Average (%) / Sector	1,154.82 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:32
Symbol	SUPN
Name	SUPERNUS PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	58.04 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,647.19 / 10,754.62

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 9715 Key West Avenue, Rockville, MD, United States, 20850

Phone: 301 838 2500

Website: https://www.supernus.com

Employees: 778

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.